Yttrium-90 Carbon Microspheres in Patients With Unresectable Hepatocellular Carcinoma
Study Details
Study Description
Brief Summary
To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
The efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable hepatocellular carcinoma remain unknown. This multicentre, prospective, open-label, single-arm trial is designed to evaluate the safety and efficacy of yttrium-90 carbon microspheres in patients with hepatocellular carcinoma. The primary endpoints are safety and local objective response rate of liver target lesions. While the secondary endpoints include the time to progression, progression-free survival rates, disease control rates, duration of response, quality of life and the distribution characteristics of yttrium-90 carbon microspheres.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Yttrium-90 carbon microspheres Single dose of yttrium-90 carbon microspheres injection. Patients will be assessed by SPECT-CT imaging within 24 hours for yttrium-90 distribution in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.Six Patients will be tested for the radioactivity of yttrium-90 in blood, urine, and feces (if available). |
Combination Product: Yttrium-90 carbon microspheres SIRT
Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
|
Outcome Measures
Primary Outcome Measures
- Adverse events [Up to 24 months]
Rates of adverse events
- Objective response rates (ORR) [3 months after yttrium-90 injection]
Liver target lesions, evaluated by the investigator and independent image review committee respectively (CTCAE 5.0)
Secondary Outcome Measures
- Hepatic time to progression (hTTP) [Up to 24 months]
Time to progression of liver target lesions, evaluated by the investigator and independent image review committee respectively (CTCAE 5.0)
- Yttrium-90 distribution [Within 24 hours]
Assessed by SPECT-CT imaging in the chest and upper abdomen, including extrahepatic shunts, intrahepatic distribution, and target lesion distribution as expected.
- Progression Free Survival Rate (PFS) [3 months after yttrium-90 injection]
Survival probability of patients without imaging progression of liver target lesions
- Time to progression (TTP) [Up to 24 months]
Time with tumor progression, evaluated by the investigator and independent image review committee respectively (CTCAE 5.0)
- Disease control rate (DCR) [Up to 24 months]
Probability of tumor control
- Duration of response (DOR) [Up to 24 months]
Time without imaging progression, evaluated by the investigator and independent image review committee respectively (CTCAE 5.0)
- Alpha fetoprotein (AFP) [Up to 24 months]
The variation of AFP levels
- Quality of life (QoL) [Up to 24 months]
The variation of QoL with EORCT QLQ-C30
- Resection rate of liver target lesions [Within 6 months]
Resection rate of liver target lesions
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Eastern Cooperative Oncology Group performance status ≤ 1;
-
Expected survival time ≥ 3 months;
-
Confirmed hepatocellular carcinoma based on EASL or AASLD guidelines;
-
Without extrahepatic metastases, inoperable or refuse surgical resection;
-
At least one well defined tumor (mRECIST 1.1);
-
Tumor burden ≤ 50% of the total liver volume;
-
Child-Pugh score ≤ 7;
-
Adequate organ function: # Blood routine [no blood transfusion or colony-stimulating factor (G-CSF) treatment within 14 days]: absolute neutrophil count ≥ 1.5 × 109/L; platelet ≥ 75 × 109/L; hemoglobin ≥ 90 g/ L; # Liver function: total bilirubin ≤ 2 times upper limit of normal (ULN); alanine transaminase and aspartate aminotransferase ≤ 5. 0 ULN; alkaline phosphatase ≤ 2.5 ULN; Albumin > 30 g/L; # Renal function: Cr ≤ 1.5 ULN; creatinine clearance ≥ 50 mL/min (calculated according to Cockcroft-Gault formula); # Coagulation function: international normalized ratio, prothrombin time and activated partial thromboplastin time were less than 1.5 ULN; # Cardiovascular function: left ventricular ejection fraction ≥ 50%;
-
According to CTCAE 5.0 standard, all adverse events of previous systematic anti-cancer treatment have recovered to baseline or ≤ 1 grade, [except for the following: neuropathy induced by previous anticancer treatment is stable (≤ 2 grade) and hair loss];
-
Women and men of childbearing age must agree to take strict and effective contraceptive measures during the study period and within 6 m after the end of the trial. Men are forbidden to donate sperm. The pregnancy test results of female patients of childbearing age during the screening period and within 24 hours before administration must be negative.
Exclusion Criteria:
-
With previous history of hepatic encephalopathy;
-
Severe pulmonary insufficiency (forced expiratory volume at one second / forced vital capacity < 50% or forced expiratory volume at one second /predicting value < 50% or maximum volume per minute < 50 L/min);Obvious chronic obstructive pulmonary disease or interstitial pneumonia;
-
Percentage of hepatopulmonary shunt > 10%, or the single lung radiation absorbed dose
30 Gy;
-
With hepatic artery malformation and unable to intubate hepatic artery;
-
Tumor thrombus in main portal vein;
-
Have received radiotherapy or transcatheter arterial chemoembolization (patients who have received transcatheter arterial non-iodized oil chemoembolization are judged by researchers);
-
The last anti-tumor treatment (surgery, chemotherapy, immunotherapy, targeted therapy) was less than 4 weeks before the drug administration;
-
Clinical manifestations of portal hypertension, moderate-severe or refractory ascites, or decompensated liver cirrhosis;
-
Participated in other trial within 1 month before yttrium-90 administration;
-
Pregnant and lactating women;
-
Serious infections in active stage or need systematic treatment;
-
With positive results of HIV antibody test;
-
The researchers judge that there is unresolved toxicity from previous treatment and will continue to exist, which may endanger the safety of patients;
-
The researcher judged clinical or laboratory examination abnormality or other reasons;
-
Extrahepatic disease or combined with other malignant tumors;
-
Hepatic artery angiography and 99mTc MAA hepatic artery perfusion imaging demonstrate gastrointestinal shunts, which may not be remedied through vascular intervention techniques.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gao-Jun Teng | Nanjing | China |
Sponsors and Collaborators
- Zhongda Hospital
Investigators
- Principal Investigator: Gao-Jun Teng, MD, Zhongda Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CHANCE2303-NRT6003-HCC